Skip to main content
. Author manuscript; available in PMC: 2019 May 20.
Published in final edited form as: Oncol Hematol Rev. 2018 Nov 27;14(2):82–88. doi: 10.17925/OHR.2018.14.2.82

Figure 1: Treatment algorithm for patients with metastatic gastroesophageal junction adenocarcinoma or esophageal adenocarcinoma.

Figure 1:

A general treatment algorithm we utilize when approaching patients with metastatic gastroesophageal junction adenocarcinoma or esophageal adenocarcinoma. Although by no means exhaustive, it does highlight the importance of considering clinical trials at all lines of therapy.

*TAS-102 also recently demonstrated third-line activity in the TAGS study and is a chemotherapy option for patients with gastroesophageal junction adenocarcinoma.

CF = cisplatin and fluorouracil; HER2 = human epidermal growth factor receptor 2; LOT = line of treatment; MSI = microsatellite instability; PD-L1 = programmed death-ligand 1.